BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reichardt W, Romaker D, Becker A, Buechert M, Walz G, von Elverfeldt D. Monitoring kidney and renal cyst volumes applying MR approaches on a rapamycin treated mouse model of ADPKD. MAGMA 2009;22:143-9. [PMID: 19107537 DOI: 10.1007/s10334-008-0158-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Gattone VH 2nd, Sinders RM, Hornberger TA, Robling AG. Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis. Kidney Int 2009;76:178-82. [PMID: 19421190 DOI: 10.1038/ki.2009.147] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
2 Edwards ME, Periyanan S, Anaam D, Gregory AV, Kline TL. Automated total kidney volume measurements in pre-clinical magnetic resonance imaging for resourcing imaging data, annotations, and source code. Kidney Int 2021;99:763-6. [PMID: 32828755 DOI: 10.1016/j.kint.2020.07.040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Kline TL. In vivo magnetic resonance imaging techniques for structural and functional characterization of murine model kidneys. Methods Cell Biol 2019;154:145-61. [PMID: 31493815 DOI: 10.1016/bs.mcb.2019.05.007] [Reference Citation Analysis]
4 Lieberthal W, Levine JS. Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications. Am J Physiol Renal Physiol 2012;303:F180-91. [PMID: 22496407 DOI: 10.1152/ajprenal.00015.2012] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
5 Nikonova AS, Deneka AY, Kiseleva AA, Korobeynikov V, Gaponova A, Serebriiskii IG, Kopp MC, Hensley HH, Seeger-Nukpezah TN, Somlo S, Proia DA, Golemis EA. Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD). FASEB J 2018;32:2735-46. [PMID: 29401581 DOI: 10.1096/fj.201700909R] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
6 Kou P, Wei S, Xiong F. Recent Advances of mTOR Inhibitors Use in Autosomal Dominant Polycystic Kidney Disease: Is the Road Still Open? Curr Med Chem 2019;26:2962-73. [PMID: 29600752 DOI: 10.2174/0929867325666180330094434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
7 Mignani R, Corsi C, De Marco M, Caiani EG, Santucci G, Cavagna E, Severi S, Cagnoli L. Assessment of kidney volume in polycystic kidney disease using magnetic resonance imaging without contrast medium. Am J Nephrol 2011;33:176-84. [PMID: 21311183 DOI: 10.1159/000324039] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
8 Franke M, Baeßler B, Vechtel J, Dafinger C, Höhne M, Borgal L, Göbel H, Koerber F, Maintz D, Benzing T, Schermer B, Persigehl T. Magnetic resonance T2 mapping and diffusion-weighted imaging for early detection of cystogenesis and response to therapy in a mouse model of polycystic kidney disease. Kidney International 2017;92:1544-54. [DOI: 10.1016/j.kint.2017.05.024] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
9 Sadick M, Attenberger U, Kraenzlin B, Kayed H, Schoenberg SO, Gretz N, Schock-Kusch D. Two non-invasive GFR-estimation methods in rat models of polycystic kidney disease: 3.0 Tesla dynamic contrast-enhanced MRI and optical imaging. Nephrol Dial Transplant 2011;26:3101-8. [PMID: 21444361 DOI: 10.1093/ndt/gfr148] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
10 Ibraghimov-Beskrovnaya O, Natoli TA. mTOR signaling in polycystic kidney disease. Trends Mol Med. 2011;17:625-633. [PMID: 21775207 DOI: 10.1016/j.molmed.2011.06.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 5.5] [Reference Citation Analysis]
11 Deneka AY, Haber L, Kopp MC, Gaponova AV, Nikonova AS, Golemis EA. Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model. PLoS One 2017;12:e0176747. [PMID: 28453558 DOI: 10.1371/journal.pone.0176747] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
12 Ta MH, Rao P, Korgaonkar M, Foster SF, Peduto A, Harris DC, Rangan GK. Pyrrolidine dithiocarbamate reduces the progression of total kidney volume and cyst enlargement in experimental polycystic kidney disease. Physiol Rep. 2014;2:pii: e12196. [PMID: 25501440 DOI: 10.14814/phy2.12196] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
13 Song T, Rao Z, Qiu Y, Liu J, Huang Z, Wang X, Lin T. Impact of remaining kidney volume to body weight ratio on renal function in living kidney donors. Kaohsiung J Med Sci 2016;32:185-90. [PMID: 27185600 DOI: 10.1016/j.kjms.2016.01.003] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
14 Xie L, Qi Y, Subashi E, Liao G, Miller-DeGraff L, Jetten AM, Johnson GA. 4D MRI of polycystic kidneys from rapamycin-treated Glis3-deficient mice. NMR Biomed 2015;28:546-54. [PMID: 25810360 DOI: 10.1002/nbm.3281] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
15 Hadjidemetriou S, Reichardt W, Buechert M, Hennig J, von Elverfeldt D. Analysis of MR images of mice in preclinical treatment monitoring of polycystic kidney disease. Med Image Comput Comput Assist Interv 2009;12:665-72. [PMID: 20426169 DOI: 10.1007/978-3-642-04271-3_81] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
16 Song T, Fu L, Huang Z, He S, Zhao R, Lin T, Wei Q. Change in renal parenchymal volume in living kidney transplant donors. Int Urol Nephrol. 2014;46:743-747. [PMID: 24178754 DOI: 10.1007/s11255-013-0592-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
17 Torres VE, Boletta A, Chapman A, Gattone V, Pei Y, Qian Q, Wallace DP, Weimbs T, Wüthrich RP. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol 2010;5:1312-29. [PMID: 20498248 DOI: 10.2215/CJN.01360210] [Cited by in Crossref: 75] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
18 Nikonova AS, Deneka AY, Eckman L, Kopp MC, Hensley HH, Egleston BL, Golemis EA. Opposing Effects of Inhibitors of Aurora-A and EGFR in Autosomal-Dominant Polycystic Kidney Disease. Front Oncol 2015;5:228. [PMID: 26528438 DOI: 10.3389/fonc.2015.00228] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
19 Hadjidemetriou S, Reichardt W, Hennig J, Buechert M, von Elverfeldt D. Volumetric analysis of MRI data monitoring the treatment of polycystic kidney disease in a mouse model. MAGMA 2011;24:109-19. [PMID: 21213015 DOI: 10.1007/s10334-010-0240-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
20 Aihara M, Fujiki H, Mizuguchi H, Hattori K, Ohmoto K, Ishikawa M, Nagano K, Yamamura Y. Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury. J Pharmacol Exp Ther 2014;349:258-67. [PMID: 24570071 DOI: 10.1124/jpet.114.213256] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]